Skip to content

A Phase 2, Double-Blind, 12 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 2 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease

Status
Suspended
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-501349-64-00
Acronym
TAK-390MR_204
Enrollment
20
Registered
2024-04-05
Start date
2023-02-01
Completion date
Unknown
Last updated
2025-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Symptomatic nonerosive GERD in paediatric subjects aged 2 to 11 years

Brief summary

The percentage of days without hurting or burning in the stomach, chest or throat over the 12 weeks of treatment.

Detailed description

Percentage of days without hurting or burning in the stomach, chest or throat in children aged 9 to 11 years over the 12 weeks of treatment., Percentage of days without hurting or burning in the stomach, chest or throat in children aged 2 to 8 years over the 12 weeks of treatment., Percentage of days without vomiting over the 12 weeks of treatment., Percentage of days food did not come up from stomach to mouth over the 12 weeks of treatment., Percentage of days without trouble eating over the 12 weeks of treatment., Comparison of the difference of the mean percentage of days without hurting or burning in the stomach, chest, or throat over the 12 weeks of treatment between the high dose and the low dose within each weight strata.

Interventions

Sponsors

Takeda Development Center Americas Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
The percentage of days without hurting or burning in the stomach, chest or throat over the 12 weeks of treatment.

Secondary

MeasureTime frame
Percentage of days without hurting or burning in the stomach, chest or throat in children aged 9 to 11 years over the 12 weeks of treatment., Percentage of days without hurting or burning in the stomach, chest or throat in children aged 2 to 8 years over the 12 weeks of treatment., Percentage of days without vomiting over the 12 weeks of treatment., Percentage of days food did not come up from stomach to mouth over the 12 weeks of treatment., Percentage of days without trouble eating over the 12 weeks of treatment., Comparison of the difference of the mean percentage of days without hurting or burning in the stomach, chest, or throat over the 12 weeks of treatment between the high dose and the low dose within each weight strata.

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026